Kyntra Bio Inc risk profile
84 Acute at or past the historical limit
Measured 21 October 2026 from KYNB's filed statements. Recomputed nightly.
84 (Acute), driven by Cash conversion at 97, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 79 | Stretched | Volatile | Drawdown from the 52-week high — 52.8% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | 97 | Acute | Easing | Capital spending against operating cash — -0.01x |
| Leverage and coverage | Reads total_debt, cash_and_cash_equivalents, ebitda, interest_expense, total_current_assets, total_current_liabilities and a disclosed CET1 ratio, for a bank or insurer. No reading is stored for this company. | |||
| Competitive position | 80 | Acute | Stable | Operating-margin gap against peers — -607.7 percentage points |
| Concentration | 86 | Acute | Stable | Geographic concentration — 7,831 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.